The Original

ROLE OF GENOMIC TECHNOLOGIES IN EARLY DISEASE DIAGNOSIS

Dr. Vamseedhar Annam[1] , Dr. K. Mahalakshmi[2], Dr. U. Karthika Priyadharshini[3] , Mr A Naga Babu[4] , Dr. T. Deborah Paripuranam[5] , Mrs. M. Krishnaveni[6]

[1]Professor, Department of Pathology, Sapthagiri Institute of Medical Sciences & Research Centre, Sapthagiri NPS University, Bengaluru, Karnataka
[2]Asst. Professor, PG Dept of Biochemistry Bhaktavatsalam Memorial College for Women, Korattur, Chennai
[3]Assistant Professor, MHPE scholar, Institute of Health Profession Education, Sri Balaji Vidyapeeth, Pondicherry Department of Physiology, Indira Gandhi Medical College & Research Institute, Pondicherry
[4]M. Pharmacy, Department of Pharmaceutics Sri Swami Vivekananda Institute of Pharmaceutical Sciences, Bhongir, Telangana
[5]Assistant Professor, Nadar Saraswathi College of Arts and Science, Theni, TN
[6]Head & Assistant Professor, Department of Biochemistry, Nadar Saraswathi College of Arts and Science (A), Vadapudhupatty, Theni, Tamilnadu

Abstract
The rapid evolution of genomic technologies has fundamentally transformed the paradigm of disease diagnosis, shifting healthcare from a reactive model toward predictive, preventive, and precision-based medicine. Conventional diagnostic approaches frequently depend on the appearance of clinical manifestations, often limiting opportunities for timely therapeutic intervention. In contrast, genomic technologies enable the identification of disease-associated molecular alterations at preclinical or asymptomatic stages, thereby facilitating early diagnosis, risk stratification, and personalized clinical management. This review critically examines recent advances in genomic technologies and their applications in the early detection of human diseases.

High-throughput sequencing platforms, particularly next-generation sequencing (NGS), including whole-genome sequencing (WGS), whole-exome sequencing (WES), targeted gene sequencing, and RNA sequencing (RNA-seq), have substantially enhanced the resolution and efficiency of genomic analyses. These approaches permit comprehensive interrogation of genomic variants, including single nucleotide variants (SNVs), insertions/deletions (indels), copy number variations (CNVs), structural variants, and epigenetic modifications that contribute to disease susceptibility and pathogenesis. Such technologies have demonstrated significant clinical utility in the early diagnosis of inherited disorders, rare genetic syndromes, oncological malignancies, cardiovascular diseases, neurodegenerative disorders, and infectious diseases.

Recent advances in non-invasive genomic diagnostics, particularly liquid biopsy-based approaches involving circulating tumor DNA (ctDNA), circulating cell-free DNA (cfDNA), extracellular vesicles, and circulating RNA biomarkers, have further expanded the scope of early disease detection. In oncology, these technologies facilitate early tumor detection, minimal residual disease assessment, and therapeutic monitoring with high sensitivity and specificity. Furthermore, genomic screening strategies, including prenatal testing, preimplantation genetic testing, and newborn genomic screening, have emerged as powerful tools for identifying pathogenic variants prior to disease onset.

The convergence of genomics with bioinformatics, artificial intelligence (AI), and machine learning (ML) has accelerated biomarker discovery and improved the interpretation of complex multi-dimensional datasets. Integrative multi-omics approaches encompassing genomics, transcriptomics, epigenomics, proteomics, and metabolomics are increasingly enabling a systems-level understanding of disease mechanisms and enhancing diagnostic accuracy. Nevertheless, the clinical translation of genomic technologies remains constrained by challenges related to data interpretation, analytical standardization, cost-effectiveness, ethical and legal considerations, data privacy, and equitable access to genomic healthcare.

In conclusion, genomic technologies represent a cornerstone of modern precision medicine, offering unprecedented opportunities for early disease diagnosis and individualized healthcare. Continued advancements in sequencing technologies, computational methodologies, and multi-omics integration are expected to further refine diagnostic capabilities and facilitate the routine implementation of genomics in clinical practice, ultimately improving patient outcomes and global health.

Keywords: Genomic technologies; Early disease diagnosis; Precision medicine; Next-generation sequencing; Whole-genome sequencing; Liquid biopsy; Cell-free DNA; Biomarkers; Multi-omics; Artificial intelligence; Molecular diagnostics; Personalized medicine.

1. INTRODUCTION

The timely detection of disease is a critical determinant of clinical outcome, therapeutic efficacy, and healthcare sustainability. A substantial proportion of morbidity and mortality associated with chronic and infectious diseases arises from delayed diagnosis, often after irreversible pathological alterations have occurred (1). Conventional diagnostic modalities, including clinical examination, biochemical assays, imaging techniques, and histopathological evaluation, have undoubtedly transformed medical practice; however, these approaches predominantly identify disease after the onset of overt clinical manifestations. Increasing evidence indicates that most pathological conditions originate from molecular perturbations that precede phenotypic expression by months, years, or even decades (2). Consequently, the identification of these early molecular signatures has emerged as a major objective in contemporary biomedical research and precision healthcare.

The concept that disease susceptibility and progression are profoundly influenced by genomic architecture has fundamentally reshaped our understanding of human health and disease. Genetic variations, epigenetic modifications, aberrant transcriptional programs, and dysregulated cellular signaling pathways collectively contribute to disease initiation and progression (3). Numerous disorders, including cancer, cardiovascular diseases, neurodegenerative disorders, metabolic syndromes, autoimmune diseases, and rare inherited conditions, possess distinct genomic and molecular landscapes that can be exploited for early diagnosis and risk prediction (4). Therefore, the ability to interrogate the human genome at high resolution has become indispensable for elucidating disease mechanisms and identifying clinically actionable biomarkers.

A transformative milestone in the evolution of genomic medicine was achieved through the completion of the Human Genome Project (HGP) in 2003, which generated the first comprehensive reference sequence of the human genome (5). This landmark accomplishment not only accelerated the discovery of disease-associated genes but also initiated an unprecedented era of genomic research characterized by rapid technological innovation and declining sequencing costs. Since then, advances in high-throughput sequencing technologies, molecular biology, computational genomics, and systems biology have revolutionized diagnostic medicine, enabling comprehensive characterization of genomic variation at an unprecedented scale and resolution (6).



Figure 1 Illustrative trend showing the dramatic reduction in the cost of sequencing a human genome over time.

Genomic technologies encompass a diverse array of molecular platforms designed to investigate the structure, function, regulation, and dynamics of the genome. These technologies include next-generation sequencing (NGS), whole-genome sequencing (WGS), whole-exome sequencing (WES), targeted sequencing panels, transcriptome sequencing (RNA-seq), chromatin accessibility assays, epigenomic profiling, genome-wide association studies (GWAS), microarray-based analyses, and emerging single-cell sequencing methodologies. Unlike conventional molecular diagnostic techniques that are typically restricted to the interrogation of a limited number of genes or biomarkers, contemporary genomic platforms facilitate the simultaneous analysis of millions of genomic loci, thereby enabling comprehensive identification of pathogenic variants and disease-associated molecular signatures.

The clinical significance of genomic technologies is particularly evident in the diagnosis of Mendelian and rare genetic disorders. It is estimated that more than 7,000 rare diseases have been identified worldwide, approximately 80% of which possess a genetic etiology. Historically, patients affected by rare diseases frequently experienced prolonged and costly diagnostic trajectories, commonly referred to as the "diagnostic odyssey." The implementation of WES and WGS has dramatically improved diagnostic yield by enabling unbiased genome-wide interrogation and identification of causative variants, including single nucleotide variants (SNVs), insertions and deletions (indels), copy number variants (CNVs), structural rearrangements, repeat expansions, and mitochondrial genomic abnormalities. Early molecular diagnosis not only facilitates timely therapeutic intervention but also informs prognosis, reproductive counseling, and family-based risk assessment.

Among all disease categories, oncology has arguably experienced the most profound impact from genomic innovation. Cancer is now widely recognized as a fundamentally genomic disease characterized by the progressive accumulation of somatic mutations, chromosomal instability, epigenetic dysregulation, and clonal evolution (7). Comprehensive genomic profiling has transformed cancer diagnostics by enabling molecular subclassification, prognostic stratification, and identification of actionable therapeutic targets. Importantly, the emergence of minimally invasive liquid biopsy technologies—including circulating tumor DNA (ctDNA), circulating cell-free DNA (cfDNA), circulating tumor cells (CTCs), exosomal nucleic acids, and other circulating biomarkers—has expanded the possibilities for early cancer detection, longitudinal disease monitoring, assessment of minimal residual disease, and prediction of therapeutic response. These approaches offer substantial advantages over conventional tissue biopsy by overcoming limitations associated with tumor heterogeneity, sampling bias, and procedural invasiveness.

Beyond oncology, genomic technologies are increasingly integrated into the diagnosis and management of a broad spectrum of complex disorders. In cardiovascular medicine, genomic screening enables early identification of inherited cardiomyopathies, arrhythmogenic syndromes, and familial hypercholesterolemia, thereby facilitating preventive interventions in at-risk individuals (8). Similarly, in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, genomic analyses have provided critical insights into disease susceptibility, pathogenic mechanisms, and potential therapeutic targets. In infectious disease diagnostics, metagenomic sequencing has emerged as a powerful tool for unbiased pathogen detection, outbreak surveillance, antimicrobial resistance profiling, and characterization of host-pathogen interactions. The global response to the COVID-19 pandemic highlighted the indispensable role of genomic surveillance in tracking viral evolution, identifying emerging variants, and informing public health interventions.

Recent technological advances have further expanded the diagnostic potential of genomics through the advent of single-cell and spatially resolved omics technologies. Single-cell sequencing platforms, including single-cell RNA sequencing (scRNA-seq), single-cell ATAC sequencing (scATAC-seq), and multi-modal single-cell approaches, enable high-resolution characterization of cellular heterogeneity and dynamic molecular states that remain obscured in bulk tissue analyses (9). These methodologies have revealed previously unrecognized cell populations, early pathogenic events, and disease-associated cellular trajectories, thereby enhancing biomarker discovery and diagnostic precision. Concurrently, spatial transcriptomics provides contextual information regarding the spatial organization of gene expression within tissues, offering novel insights into tissue architecture and microenvironmental interactions during disease progression.

The integration of genomics with complementary omics disciplines, including transcriptomics, epigenomics, proteomics, metabolomics, and microbiomics, has given rise to multi-omics approaches that facilitate a comprehensive systems-level understanding of biological processes. Such integrative strategies are increasingly recognized as essential for deciphering the complexity of multifactorial diseases, identifying robust diagnostic biomarkers, and advancing precision medicine. Furthermore, the exponential growth of genomic datasets has stimulated the development of sophisticated bioinformatic pipelines and artificial intelligence (AI)-driven analytical frameworks. Machine learning and deep learning algorithms are now routinely employed for variant interpretation, disease risk prediction, biomarker discovery, patient stratification, and clinical decision support, significantly enhancing the translational potential of genomic medicine.

Despite these remarkable advances, several scientific, technical, ethical, and socioeconomic challenges continue to impede the widespread implementation of genomic technologies in routine clinical practice. Interpretation of variants of uncertain significance (VUS), limited representation of diverse populations in genomic databases, data standardization issues, regulatory constraints, concerns regarding privacy and data security, and disparities in access to genomic healthcare remain major barriers to clinical translation. In addition, the integration of large-scale genomic information into healthcare systems necessitates substantial investments in infrastructure, workforce training, and evidence-based policy development.

Given the rapid expansion of genomic research and its increasing clinical relevance, a comprehensive evaluation of current genomic technologies and their diagnostic applications is essential. Therefore, this review critically examines the major genomic platforms employed in early disease diagnosis, highlights their applications across diverse disease domains, discusses emerging innovations such as single-cell and multi-omics approaches, and evaluates the challenges and future perspectives associated with the integration of genomic technologies into precision healthcare systems.

2. MAJOR GENOMIC TECHNOLOGIES IN EARLY DISEASE DIAGNOSIS

2.1 Next-Generation Sequencing (NGS): Principles and Clinical Applications

Next-generation sequencing (NGS) represents one of the most significant advancements in genomic medicine, enabling the rapid and simultaneous sequencing of millions of DNA fragments. Unlike traditional Sanger sequencing, which analyzes a single DNA fragment at a time, NGS employs massively parallel sequencing, thereby significantly increasing throughput while reducing cost and processing time (10). The typical NGS workflow involves DNA or RNA extraction, library preparation, sequencing, and bioinformatic analysis. Modern NGS platforms, such as Illumina, Ion Torrent, and Oxford Nanopore technologies, have transformed molecular diagnostics by facilitating comprehensive genomic analyses.

NGS has extensive applications in early disease diagnosis, including the detection of inherited genetic disorders, cancer-associated mutations, infectious agents, and pharmacogenomic variants. In oncology, NGS enables the identification of actionable mutations in genes such as BRCA1, BRCA2, EGFR, and TP53, thereby supporting early diagnosis and targeted therapy selection. Moreover, NGS-based pathogen sequencing has emerged as a powerful tool for rapid identification of infectious organisms and antimicrobial resistance determinants. The high sensitivity, scalability, and multiplexing capacity of NGS make it an indispensable technology in precision medicine.

2.2 Whole-Genome Sequencing (WGS) for Comprehensive Genomic Profiling

Whole-genome sequencing (WGS) is a comprehensive sequencing approach that determines the complete nucleotide sequence of an organism's genome, encompassing both coding and non-coding regions (11). Unlike targeted sequencing approaches, WGS provides an unbiased assessment of the entire genomic landscape, enabling the detection of diverse genomic alterations, including single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), structural variants, and chromosomal rearrangements.

WGS has demonstrated considerable clinical utility in the diagnosis of rare and undiagnosed diseases, particularly when conventional diagnostic approaches fail to identify the underlying genetic cause. The ability of WGS to capture regulatory and non-coding variants offers significant advantages over exome-focused approaches. Additionally, WGS has become increasingly important in cancer genomics, infectious disease surveillance, and population-based genomic studies. Despite its comprehensive nature, challenges related to data interpretation, storage requirements, and cost continue to limit its widespread clinical implementation.

2.3 Whole-Exome Sequencing (WES) in Precision Diagnostics

Whole-exome sequencing (WES) selectively sequences the protein-coding regions of the genome, collectively known as the exome, which constitutes approximately 1–2% of the human genome but harbors nearly 85% of known disease-causing mutations. By focusing on coding regions, WES offers a cost-effective alternative to WGS while maintaining high diagnostic efficiency.

WES has revolutionized the diagnosis of Mendelian disorders, rare genetic diseases, neurodevelopmental disorders, and inherited metabolic syndromes. The technology enables the identification of pathogenic variants in genes associated with disease phenotypes, thereby significantly reducing diagnostic delays (12). Furthermore, WES facilitates genotype-phenotype correlations and supports personalized clinical decision-making. However, WES has inherent limitations, including incomplete coverage of certain exons and inability to reliably detect structural variants or pathogenic alterations located in non-coding genomic regions.



Figure 2 Major clinical applications of genomic technologies.

2.4 Transcriptomics and RNA Sequencing in Disease Biomarker Discovery

Transcriptomics refers to the comprehensive analysis of RNA transcripts expressed within a cell or tissue under specific physiological or pathological conditions. RNA sequencing (RNA-seq) has emerged as the gold-standard transcriptomic technology, enabling quantitative and qualitative assessment of gene expression patterns with high sensitivity and resolution.

RNA-seq provides critical insights into dynamic cellular processes by identifying differentially expressed genes, alternative splicing events, gene fusions, and non-coding RNAs. These molecular signatures can serve as valuable biomarkers for early disease detection, prognosis, and therapeutic response prediction. In cancer diagnostics, transcriptomic profiling has facilitated molecular subtyping and identification of disease-specific expression signatures (13). Similarly, transcriptomics has contributed substantially to understanding the molecular mechanisms underlying neurodegenerative disorders, autoimmune diseases, and infectious diseases. Nevertheless, RNA instability and tissue-specific expression variability remain important technical challenges.

2.5 Single-Cell Genomics: Deciphering Cellular Heterogeneity

Conventional bulk genomic analyses often obscure cellular heterogeneity by averaging molecular signals across diverse cell populations. Single-cell genomics overcomes this limitation by enabling genomic, transcriptomic, and epigenomic analyses at the resolution of individual cells. Among these technologies, single-cell RNA sequencing (scRNA-seq) has become particularly valuable for characterizing cellular diversity and identifying rare cell populations.

Single-cell technologies have significantly advanced the understanding of disease pathogenesis by revealing previously unrecognized cellular subpopulations, developmental trajectories, and disease-associated molecular states. In oncology, single-cell analyses enable characterization of intratumoral heterogeneity, clonal evolution, and mechanisms of therapeutic resistance (14). In immunology, these approaches facilitate detailed profiling of immune cell populations involved in disease progression. Consequently, single-cell genomics has emerged as a promising tool for biomarker discovery and early disease diagnosis, although high costs, complex data analysis, and technical variability remain important limitations.

2.6 Epigenomic and Integrative Multi-omics Approaches

Disease development is influenced not only by genetic variations but also by epigenetic modifications that regulate gene expression without altering DNA sequence. Epigenomics encompasses the genome-wide study of epigenetic mechanisms, including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA-mediated regulation. Aberrant epigenetic alterations frequently occur during the earliest stages of disease development, making them attractive biomarkers for early diagnosis.

Table 1. Major Genomic Technologies Used in Early Disease Diagnosis: Principles, Applications, Advantages, and Limitations

Technology	Principle	Genomic Target	Major Applications in Early Disease Diagnosis	Advantages
Next-Generation Sequencing (NGS)	Massively parallel sequencing of millions of DNA/RNA fragments simultaneously	DNA and RNA	Detection of inherited disorders, cancer mutations, infectious diseases, and pharmacogenomic profiling	High throughput, rapid, cost-effective for large-scale studies, high sensitivity
Whole-Genome Sequencing (WGS)	Sequencing of the complete genomic DNA, including coding and non-coding regions	Entire genome	Comprehensive identification of genetic variants in rare diseases, cancer, and complex disorders	Provides unbiased and comprehensive genomic information; detects structural and non-coding variants
Whole-Exome Sequencing (WES)	Selective sequencing of protein-coding regions (exons)	Exome (~1–2% of genome)	Diagnosis of Mendelian disorders, rare genetic diseases, and neurodevelopmental disorders	Cost-effective, high diagnostic yield, clinically established
Transcriptomics/RNA Sequencing (RNA-seq)	Sequencing and quantification of RNA transcripts to assess gene expression	Transcriptome	Biomarker discovery, disease classification, cancer subtyping, and prognosis	Detects differential gene expression, alternative splicing, and fusion transcripts
Single-Cell Genomics	Genomic and transcriptomic analysis at individual cell resolution	Single cells	Identification of cellular heterogeneity, rare cell populations, and early pathogenic events	High-resolution analysis, reveals cell-specific molecular signatures
Epigenomic and Multi-omics Approaches	Analysis and integration of epigenetic modifications and multiple omics datasets	Epigenome and multiple molecular layers	Early biomarker identification, disease risk prediction, and precision diagnostics	Provides systems-level understanding of disease mechanisms

Recent advances have increasingly emphasized integrative multi-omics approaches, which combine genomics with transcriptomics, proteomics, metabolomics, and epigenomics to achieve a comprehensive understanding of biological systems (15). Multi-omics integration enables the identification of robust biomarkers and provides systems-level insights into disease mechanisms that cannot be obtained through single-omics analyses alone. The incorporation of artificial intelligence and machine learning into multi-omics data analysis has further enhanced biomarker discovery and disease prediction. Although multi-omics approaches hold tremendous promise for precision diagnostics, challenges related to data integration, standardization, computational complexity, and clinical translation remain to be addressed.

3. APPLICATIONS OF GENOMIC TECHNOLOGIES IN EARLY DISEASE DIAGNOSIS

The integration of genomic technologies into clinical medicine has fundamentally transformed the landscape of disease diagnosis by enabling the detection of molecular abnormalities long before the onset of overt clinical manifestations. Advances in high-throughput sequencing, transcriptomics, epigenomics, and multi-omics have facilitated the identification of disease-associated genetic variants, molecular biomarkers, and pathogenic mechanisms with unprecedented sensitivity and specificity (16). Consequently, genomic approaches have become central to precision medicine, supporting early diagnosis, disease risk stratification, prognostication, and individualized therapeutic interventions across a broad spectrum of diseases.

3.1 Genetic and Rare Diseases

Rare diseases collectively affect millions of individuals worldwide and represent a substantial global health burden. Approximately 80% of rare diseases are estimated to have a genetic origin, encompassing a diverse range of Mendelian disorders, chromosomal abnormalities, mitochondrial diseases, and inherited metabolic syndromes. Historically, establishing a definitive diagnosis for these conditions has been challenging, often resulting in a prolonged and costly diagnostic journey, commonly referred to as the "diagnostic odyssey."

The advent of genomic technologies, particularly whole-exome sequencing (WES) and whole-genome sequencing (WGS), has dramatically improved diagnostic capabilities for rare and inherited disorders. These technologies enable comprehensive identification of pathogenic variants, including single nucleotide variants (SNVs), insertions and deletions (indels), copy number variants (CNVs), structural rearrangements, repeat expansions, and mitochondrial DNA mutations. Numerous studies have demonstrated that WES and WGS substantially increase diagnostic yield in patients with previously unexplained clinical phenotypes.

Genomic analyses have been successfully applied to diagnose disorders such as cystic fibrosis (CFTR mutations), Duchenne muscular dystrophy (DMD mutations), Rett syndrome (MECP2 mutations), spinal muscular atrophy (SMN1 deletions), and various inherited metabolic disorders. Early molecular diagnosis facilitates timely clinical intervention, targeted treatment, prognosis determination, family counseling, carrier detection, and informed reproductive decision-making (17). Moreover, genomic diagnosis contributes significantly to expanding the understanding of genotype–phenotype relationships and the discovery of novel disease-associated genes.

3.2 Cancer Diagnosis and Liquid Biopsy

Cancer is increasingly recognized as a genomic disease driven by the accumulation of somatic mutations, chromosomal instability, epigenetic dysregulation, and clonal evolution. Comprehensive characterization of these molecular alterations has transformed cancer diagnostics and enabled the implementation of precision oncology strategies.

Next-generation sequencing (NGS)-based tumor profiling has become an essential component of modern oncological practice. Genomic analysis enables the identification of clinically actionable mutations in genes such as TP53, BRCA1, BRCA2, EGFR, KRAS, BRAF, and PIK3CA, thereby facilitating molecular classification, prognostic assessment, and selection of targeted therapies. Furthermore, transcriptomic and epigenomic profiling have improved the molecular subclassification of cancers, contributing to more accurate diagnosis and personalized treatment planning.



Figure 3 Distribution of genomic technologies in clinical technologies

A major advancement in cancer diagnostics is the development of liquid biopsy, a minimally invasive approach that analyzes tumor-derived biomarkers present in body fluids. Liquid biopsy primarily involves the detection of circulating tumor DNA (ctDNA), circulating cell-free DNA (cfDNA), circulating tumor cells (CTCs), extracellular

vesicles, microRNAs, and other circulating nucleic acids. These biomarkers provide valuable insights into tumor dynamics and can be detected even during early stages of disease development.
Liquid biopsy offers several advantages over conventional tissue biopsy, including reduced procedural invasiveness, real-time monitoring, repeated sampling capability, and improved assessment of intratumoral heterogeneity (18). Clinically, liquid biopsy has demonstrated utility in early cancer detection, monitoring minimal residual disease, evaluating therapeutic response, identifying mechanisms of drug resistance, and detecting disease recurrence. Consequently, liquid biopsy is increasingly being integrated into routine oncological practice and is expected to play a pivotal role in future cancer screening programs.

3.3 Cardiovascular Diseases

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality globally. Although environmental and lifestyle factors significantly influence cardiovascular risk, genetic predisposition plays a crucial role in the pathogenesis of many inherited and complex cardiovascular disorders.
Genomic technologies have significantly advanced the early diagnosis of hereditary cardiovascular conditions, including familial hypercholesterolemia, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic cardiomyopathy, and inherited arrhythmia syndromes. Sequencing-based approaches enable the identification of pathogenic variants in genes such as LDLR, APOB, PCSK9, MYH7, MYBPC3, and SCN5A, thereby facilitating risk assessment and early clinical intervention.
In addition to monogenic disorders, genome-wide association studies (GWAS) have identified numerous susceptibility loci associated with complex cardiovascular diseases, including coronary artery disease, hypertension, and atrial fibrillation. These discoveries have enabled the development of polygenic risk scores (PRS), which integrate the cumulative effects of multiple genetic variants to predict disease susceptibility. Early genomic screening, combined with lifestyle modification and preventive strategies, has the potential to substantially reduce the burden of cardiovascular disease.

3.4 Neurodegenerative Disorders

Neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), are characterized by progressive neuronal dysfunction and irreversible neurological decline (19). Since pathological processes often precede clinical symptoms by several years, early diagnosis remains a major challenge in neurology.
Genomic technologies have considerably improved understanding of the molecular basis of neurodegeneration. Variants in genes such as APP, PSEN1, PSEN2, APOE, SNCA, HTT, and C9orf72 have been implicated in disease susceptibility, progression, and phenotypic variability. Whole-genome sequencing, transcriptomic profiling, and epigenomic analyses have identified novel molecular pathways involved in neuronal degeneration, neuroinflammation, and synaptic dysfunction.
Recent advances in single-cell sequencing technologies have further enhanced the understanding of cellular heterogeneity within the central nervous system. Single-cell transcriptomics enables the identification of disease-specific cellular populations and early molecular alterations that may serve as diagnostic biomarkers. These discoveries provide promising opportunities for pre-symptomatic diagnosis, disease stratification, and the development of targeted therapeutic interventions.

3.5 Infectious Diseases

Rapid and accurate identification of infectious agents is essential for effective patient management, antimicrobial stewardship, and outbreak control. Traditional culture-based diagnostic methods are often time-consuming and may fail to detect fastidious, unculturable, or previously unknown pathogens.
Genomic technologies, particularly metagenomic next-generation sequencing (mNGS), have revolutionized infectious disease diagnostics by enabling culture-independent, unbiased pathogen detection directly from clinical specimens (20). Unlike conventional assays that target specific organisms, mNGS simultaneously identifies bacterial, viral, fungal, and parasitic pathogens, making it particularly valuable in cases of atypical infections, mixed infections, and unexplained clinical syndromes.
In addition to pathogen identification, genomic sequencing facilitates antimicrobial resistance profiling, molecular epidemiology, and genomic surveillance of emerging infectious agents. The COVID-19 pandemic highlighted the indispensable role of genomic surveillance in tracking SARS-CoV-2 evolution, identifying variants of concern, understanding transmission dynamics, and informing public health interventions. Consequently, genomic technologies have become integral components of modern infectious disease management and global health preparedness.

3.6 Prenatal and Newborn Screening

Prenatal and newborn screening constitute one of the most successful implementations of genomic medicine in preventive healthcare. Early identification of genetic abnormalities during fetal development or shortly after birth enables timely therapeutic intervention, reduces disease-related complications, and improves long-term clinical outcomes.

Non-invasive prenatal testing (NIPT), based on the analysis of fetal cell-free DNA circulating in maternal plasma, has transformed prenatal diagnostics. NIPT provides highly sensitive and specific screening for common chromosomal aneuploidies, including trisomy 21, trisomy 18, and trisomy 13, while minimizing the risks associated with invasive procedures such as chorionic villus sampling and amniocentesis.

Similarly, genomic technologies are increasingly being incorporated into newborn screening programs to detect inherited metabolic disorders, primary immunodeficiencies, endocrine disorders, and other actionable genetic conditions at pre-symptomatic stages. Whole-exome sequencing and whole-genome sequencing have demonstrated substantial potential for expanding conventional newborn screening by enabling comprehensive genomic assessment (21). However, widespread implementation requires careful consideration of ethical, legal, and social issues, including informed consent, incidental findings, data privacy, and long-term management of genomic information.

Table 2. Clinical Applications of Genomic Technologies in Early Disease Diagnosis

Disease Category	Major Genomic Technologies	Representative Biomarkers/Genes	Clinical Utility
Rare Genetic Diseases	WES, WGS	CFTR, DMD, MECP2	Definitive molecular diagnosis
Cancer	NGS, Liquid biopsy	BRCA1/2, EGFR, KRAS, ctDNA	Early detection and targeted therapy
Cardiovascular Diseases	NGS, GWAS	LDLR, MYH7, SCN5A	Risk prediction and preventive care
Neurodegenerative Disorders	WGS, Transcriptomics	APOE, APP, PSEN1	Early diagnosis and disease monitoring
Infectious Diseases	mNGS	Pathogen genomes, resistance genes	Rapid pathogen identification
Prenatal/Newborn Screening	NIPT, WES, WGS	Chromosomal abnormalities	Early intervention and prevention

4. INTEGRATION OF ARTIFICIAL INTELLIGENCE AND BIOINFORMATICS IN GENOMIC DIAGNOSTICS

The rapid advancement of high-throughput genomic technologies has resulted in the generation of enormous volumes of complex biological data, presenting significant challenges in data processing, interpretation, and clinical translation (22). Modern genomic datasets encompass information derived from whole-genome sequencing, transcriptomics, epigenomics, proteomics, metabolomics, and single-cell sequencing, producing multidimensional data that cannot be effectively analyzed using conventional statistical approaches alone. Consequently, bioinformatics, artificial intelligence (AI), and machine learning (ML) have emerged as indispensable tools for extracting biologically meaningful information from genomic data and facilitating its application in precision medicine.

Bioinformatics provides the computational foundation for genomic diagnostics through the development of algorithms, databases, and analytical pipelines for sequence alignment, variant calling, annotation, and functional interpretation. Public repositories such as GenBank, ClinVar, dbSNP, COSMIC, and The Cancer Genome Atlas (TCGA) have become invaluable resources for understanding the clinical significance of genomic variants. The integration of these resources with computational approaches enables the identification of disease-associated genes, molecular pathways, and clinically actionable mutations (23). Furthermore, advanced bioinformatic tools facilitate the analysis of large-scale sequencing data, thereby accelerating the translation of genomic discoveries into clinical practice.

4.1 Artificial Intelligence and Machine Learning for Genomic Data Analysis

Artificial intelligence refers to computational systems capable of performing tasks that typically require human intelligence, whereas machine learning represents a subset of AI that enables algorithms to learn patterns from data and make predictions without explicit programming. In genomics, AI and ML methodologies have become increasingly important because of the unprecedented volume and complexity of genomic datasets.

Machine learning approaches can be broadly categorized into supervised, unsupervised, and deep learning methods. Supervised learning algorithms, including support vector machines (SVM), random forests, and gradient boosting methods, are widely employed for disease classification and prediction of pathogenic variants. Unsupervised learning techniques, such as clustering and principal component analysis, are used to identify hidden patterns, molecular subtypes, and novel disease classifications. Deep learning approaches, particularly convolutional neural networks (CNNs) and recurrent neural networks (RNNs), have demonstrated exceptional performance in genomic sequence analysis, variant prioritization, and functional annotation of non-coding regions.

AI-driven approaches have significantly improved the accuracy of variant interpretation by distinguishing pathogenic mutations from benign polymorphisms. Moreover, machine learning models are increasingly being applied to predict gene function, identify regulatory elements, characterize genomic interactions, and uncover complex genotype-phenotype relationships. The integration of AI with genomic technologies has therefore become a cornerstone of modern precision diagnostics.

4.2 Biomarker Discovery and Risk Prediction

One of the most promising applications of AI in genomics is the identification of diagnostic and prognostic biomarkers. Traditional biomarker discovery approaches are often limited by the high dimensionality and complexity of genomic data. Machine learning algorithms, however, can simultaneously analyze thousands of variables and identify subtle molecular signatures that may be overlooked using conventional analytical methods.

AI-based approaches have facilitated the discovery of biomarkers across numerous disease categories, including cancer, cardiovascular diseases, neurodegenerative disorders, and autoimmune conditions. In oncology, machine learning algorithms have successfully identified gene expression signatures associated with early tumor detection, metastasis, and treatment response. Similarly, in cardiovascular medicine, genomic biomarkers have been utilized to predict disease susceptibility and adverse clinical outcomes.

Risk prediction models based on genomic information have also gained considerable attention in recent years. Polygenic risk scores (PRS), which integrate the cumulative effects of multiple genetic variants, have emerged as valuable tools for predicting an individual's susceptibility to complex diseases such as coronary artery disease, type 2 diabetes, breast cancer, and Alzheimer's disease. The incorporation of AI methodologies into PRS development has substantially improved predictive performance and enabled more accurate patient stratification.

Furthermore, the integration of genomic data with clinical, environmental, and lifestyle factors has enabled the development of comprehensive predictive models that support personalized disease prevention and early intervention strategies.



Figure 4 AI integration versus diagnostic accuracy.

4.3 Clinical Decision Support Systems

The increasing complexity of genomic information has created an urgent need for computational tools capable of translating genomic findings into clinically actionable recommendations. Clinical Decision Support Systems (CDSS)

are computer-based platforms that integrate genomic, clinical, and demographic data to assist healthcare professionals in diagnosis, prognosis, and therapeutic decision-making.
AI-powered CDSS can rapidly analyze large genomic datasets and provide evidence-based recommendations regarding disease diagnosis, risk assessment, and treatment selection. In oncology, genomic decision-support platforms facilitate the interpretation of tumor sequencing data and identify potential targeted therapies based on molecular profiles. Similarly, in pharmacogenomics, CDSS can predict drug efficacy and adverse drug reactions based on an individual's genetic background, thereby supporting personalized medicine.
The integration of AI into clinical decision support has improved diagnostic accuracy, reduced interpretation time, and enhanced the consistency of clinical decision-making. Nevertheless, challenges remain regarding algorithm transparency, model interpretability, validation across diverse populations, and integration into existing healthcare infrastructures.

4.4 Big Data Analytics in Precision Medicine

The era of genomic medicine is characterized by the generation of massive volumes of biological data, commonly referred to as "big data." Genomic datasets are distinguished by their volume, velocity, variety, and complexity, necessitating advanced computational approaches for efficient storage, management, and analysis.
Big data analytics combines bioinformatics, cloud computing, artificial intelligence, and advanced statistical methodologies to derive meaningful insights from large-scale biomedical datasets. The integration of genomic information with transcriptomic, proteomic, metabolomic, imaging, and electronic health record (EHR) data has substantially expanded the capabilities of precision medicine.
Large-scale genomic initiatives, including population biobanks and international sequencing consortia, have generated extensive datasets that enable the identification of novel disease-associated variants, molecular pathways, and therapeutic targets. Big data approaches also facilitate the development of predictive models for disease susceptibility, progression, and treatment response.
The convergence of big data analytics, artificial intelligence, and genomics has accelerated the transition from traditional reactive healthcare toward predictive, preventive, personalized, and participatory (P4) medicine. However, several challenges remain, including data interoperability, standardization, privacy protection, computational infrastructure requirements, and ethical considerations associated with large-scale genomic data sharing.
Overall, the integration of artificial intelligence and bioinformatics into genomic diagnostics represents one of the most transformative developments in modern medicine. By enabling efficient analysis and interpretation of complex genomic datasets, these technologies are enhancing diagnostic precision, facilitating biomarker discovery, improving risk prediction, and ad vancing the implementation of precision medicine in clinical practice.

Table 3. Applications of Artificial Intelligence and Bioinformatics in Genomic Diagnostics

Application Area	AI/Bioinformatics Tools	Clinical Applications	Benefits
Variant Calling and Annotation	GATK, DeepVariant, ANNOVAR	Identification of pathogenic mutations	Improved diagnostic accuracy
Biomarker Discovery	Random Forest, SVM, Neural Networks	Identification of disease biomarkers	Early disease detection
Risk Prediction	Polygenic Risk Scores, Deep Learning Models	Prediction of disease susceptibility	Personalized prevention strategies
Clinical Decision Support	AI-powered CDSS	Treatment selection and diagnosis	Improved clinical decision-making
Multi-omics Integration	Machine Learning and Network Analysis	Precision medicine and patient stratification	Comprehensive disease understanding
Big Data Analytics	Cloud Computing, AI Platforms	Population genomics and genomic surveillance	Large-scale data interpretation

5. CHALLENGES, ETHICAL CONSIDERATIONS, AND LIMITATIONS

Despite the remarkable advances in genomic technologies and their transformative impact on early disease diagnosis, several scientific, technical, ethical, and socioeconomic challenges continue to impede their widespread clinical implementation (24). The increasing integration of genomics into healthcare has generated unprecedented opportunities for precision medicine; however, it has simultaneously introduced complex issues related to data interpretation, ethical governance, privacy protection, and equitable access. Addressing these challenges is essential to ensure the responsible, effective, and sustainable integration of genomic technologies into routine clinical practice.

5.1 Data Interpretation Challenges

One of the most significant barriers to the clinical translation of genomic technologies is the interpretation of the vast and complex datasets generated by high-throughput sequencing platforms. Modern genomic approaches, including whole-genome sequencing (WGS), whole-exome sequencing (WES), and multi-omics analyses, routinely identify thousands to millions of genetic variants in an individual genome. Distinguishing clinically relevant pathogenic variants from benign polymorphisms remains a formidable challenge.

The functional significance of many genomic variants remains poorly understood, particularly those located in non-coding regions of the genome. Although numerous computational tools and bioinformatics pipelines have been developed for variant annotation and prioritization, inconsistencies among analytical methods frequently result in discrepancies in variant classification (25). Moreover, the interpretation of genomic data often requires integration with phenotypic, clinical, and family history information, emphasizing the need for multidisciplinary expertise involving clinicians, molecular geneticists, bioinformaticians, and genetic counselors.

Another challenge is the limited representation of diverse populations in existing genomic databases. Most reference datasets have been derived predominantly from populations of European ancestry, thereby reducing the accuracy of variant interpretation in underrepresented populations. Expanding genomic diversity within global reference databases is therefore crucial for improving diagnostic accuracy and reducing healthcare inequities.

5.2 Variants of Uncertain Significance (VUS)

The identification of variants of uncertain significance (VUS) represents one of the most challenging aspects of clinical genomics. A VUS is defined as a genetic variant for which the available evidence is insufficient to determine whether it is pathogenic or benign. As genomic sequencing becomes increasingly comprehensive, the number of identified VUS continues to rise substantially.

The presence of VUS creates significant challenges for both clinicians and patients because their clinical implications remain unclear. Uncertain findings may complicate clinical decision-making, delay diagnosis, and generate psychological distress among patients and families. Furthermore, inappropriate interpretation of VUS may result in unnecessary medical interventions or inaccurate risk assessment.

To address this issue, international organizations such as the American College of Medical Genetics and Genomics (ACMG) have developed standardized guidelines for variant classification. Functional studies, segregation analyses, population frequency data, and computational predictions are increasingly employed to reclassify VUS over time. Advances in artificial intelligence, machine learning, and large-scale functional genomics are expected to improve the interpretation and clinical utility of uncertain variants in the future.\

5.3 Ethical, Legal, and Social Implications (ELSI)

The widespread implementation of genomic technologies raises numerous ethical, legal, and social implications (ELSI) that require careful consideration. Genomic information is inherently sensitive because it not only pertains to an individual but may also reveal information about biological relatives and future generations.

One major ethical concern involves informed consent. Patients undergoing genomic testing must fully understand the scope, benefits, limitations, and potential consequences of testing, including the possibility of incidental or secondary findings. Such findings may reveal unexpected information unrelated to the primary indication for testing, such as predisposition to hereditary cancers or neurodegenerative disorders.

Another important issue concerns genetic discrimination. Individuals may face discrimination in employment, insurance, or social settings based on their genetic information. Consequently, robust legal frameworks and anti-discrimination policies are necessary to protect individuals from potential misuse of genomic data.

Additional ethical considerations include reproductive decision-making, prenatal testing, newborn genomic screening, return of genomic results, ownership of genomic information, and the responsible use of emerging technologies such as gene editing. The development of internationally harmonized ethical guidelines and regulatory frameworks is therefore essential for ensuring responsible genomic practice.

5.4 Data Privacy and Security

The increasing digitization and large-scale sharing of genomic data have intensified concerns regarding data privacy and cybersecurity. Unlike many other forms of medical information, genomic data are permanent, uniquely identifiable, and highly sensitive. Even anonymized genomic datasets may potentially be re-identified when combined with other demographic or health-related information.

The storage, transfer, and analysis of genomic information frequently involve cloud-based infrastructures, international collaborations, and large-scale databases, thereby increasing vulnerability to unauthorized access, data breaches, and cyberattacks. Ensuring the confidentiality, integrity, and security of genomic data is therefore a critical priority.

Several strategies have been proposed to enhance genomic data protection, including data encryption, secure cloud computing, blockchain technologies, federated data-sharing models, and strict access-control mechanisms. Furthermore, compliance with national and international regulatory frameworks governing data protection is essential to maintain public trust and facilitate responsible data sharing in genomic research and clinical practice.

5.5 Cost, Accessibility, and Healthcare Disparities

Although the cost of genomic sequencing has declined dramatically over the past two decades, financial barriers remain a significant obstacle to widespread implementation, particularly in low- and middle-income countries. Comprehensive genomic analyses, including WGS, single-cell sequencing, and multi-omics profiling, continue to require substantial investments in laboratory infrastructure, computational resources, and specialized personnel.

Limited availability of sequencing facilities, bioinformatics expertise, and genetic counseling services further restricts access to genomic healthcare in resource-constrained settings. Consequently, disparities in access to genomic technologies may exacerbate existing healthcare inequalities both within and between countries.

In addition, underrepresentation of diverse ethnic populations in genomic research has limited the generalizability of genomic discoveries and reduced diagnostic accuracy for many non-European populations. Addressing these disparities requires increased investment in genomic infrastructure, workforce development, international collaborations, and inclusive research initiatives that encompass diverse populations.

Overall, while genomic technologies hold immense promise for revolutionizing early disease diagnosis, their successful clinical integration depends on overcoming numerous scientific, ethical, and socioeconomic challenges. Continued efforts aimed at improving data interpretation, strengthening ethical governance, ensuring data security, and promoting equitable access will be essential for realizing the full potential of genomic medicine.

Table 4. Major Challenges and Ethical Considerations in Genomic Diagnostics

Challenge Category	Key Issues	Potential Impact	Possible Mitigation Strategies
Data Interpretation	Complex genomic datasets, limited functional annotation	Misclassification of variants	Improved bioinformatics tools and functional validation
Variants of Uncertain Significance (VUS)	Insufficient evidence regarding pathogenicity	Diagnostic uncertainty	Standardized guidelines and continuous re-evaluation
Ethical, Legal, and Social Issues	Informed consent, incidental findings, genetic discrimination	Ethical conflicts and misuse of data	Regulatory frameworks and ethical oversight
Data Privacy and Security	Data breaches, unauthorized access, re-identification risks	Loss of confidentiality and public trust	Encryption, secure databases, blockchain technologies
Cost and Accessibility	High costs, limited infrastructure, workforce shortages	Unequal access to genomic medicine	Investment in infrastructure and equitable healthcare policies

7. CONCLUSION

The unprecedented advances in genomic technologies over the past two decades have fundamentally redefined the paradigm of disease diagnosis, transitioning clinical practice from conventional symptom-driven approaches toward molecularly informed precision medicine. High-throughput genomic platforms, including next-generation sequencing (NGS), whole-genome sequencing (WGS), whole-exome sequencing (WES), transcriptomics, single-cell genomics, and integrative multi-omics technologies, have substantially enhanced our ability to identify disease-associated molecular alterations at preclinical and asymptomatic stages. These technologies have not only improved diagnostic accuracy and sensitivity but have also provided unprecedented insights into the genetic and molecular mechanisms underlying human diseases.

The evidence presented in this review underscores the transformative role of genomic technologies in the early diagnosis of a broad spectrum of disorders, including rare genetic diseases, cancer, cardiovascular disorders, neurodegenerative diseases, infectious diseases, and prenatal abnormalities. The identification of pathogenic variants, gene expression signatures, epigenetic alterations, and circulating biomarkers has facilitated earlier and more precise disease detection, thereby enabling timely clinical intervention, improved prognostic assessment, and personalized therapeutic decision-making. In particular, emerging diagnostic modalities such as liquid biopsy, metagenomic sequencing, and single-cell analyses are reshaping contemporary diagnostic strategies by enabling minimally invasive, high-resolution, and real-time assessment of disease dynamics.

Furthermore, the convergence of genomics with bioinformatics, artificial intelligence (AI), machine learning (ML), and big data analytics has significantly accelerated the interpretation of complex genomic datasets and enhanced biomarker discovery, disease risk prediction, and clinical decision support. The integration of multi-omics datasets within advanced computational frameworks is increasingly facilitating a systems-level understanding of disease pathophysiology, thereby strengthening the implementation of precision and predictive medicine.

Despite these remarkable achievements, several scientific, technical, ethical, and socioeconomic challenges continue to impede the widespread clinical translation of genomic technologies. Limitations associated with variant interpretation, variants of uncertain significance (VUS), incomplete representation of global populations in genomic databases, data privacy and security concerns, ethical and legal complexities, and disparities in access to genomic healthcare remain substantial barriers. Addressing these challenges will require the establishment of standardized analytical pipelines, expansion of diverse population-based genomic resources, robust regulatory and ethical frameworks, and sustained investment in infrastructure, workforce development, and interdisciplinary collaboration.

Looking ahead, continuous innovations in long-read sequencing, single-cell and spatial omics, epigenomic profiling, multi-omics integration, and AI-driven analytical methodologies are expected to further refine the sensitivity, specificity, and clinical utility of genomic diagnostics. The routine incorporation of genomic technologies into healthcare systems holds immense potential for enabling pre-symptomatic disease detection, individualized risk stratification, targeted therapeutic interventions, and proactive disease prevention. Ultimately, the successful integration of genomics into clinical practice will accelerate the realization of predictive, preventive, personalized, and participatory (P4) medicine, thereby transforming healthcare delivery and improving global health outcomes.

REFERENCES

1. Ashley, E. A. (2016). Towards precision medicine. Nature Reviews Genetics, 17(9), 507–522. https://doi.org/10.1038/nrg.2016.86
2. Biesecker, L. G., & Green, R. C. (2014). Diagnostic clinical genome and exome sequencing. The New England Journal of Medicine, 370(25), 2418–2425. https://doi.org/10.1056/NEJMra1312543
3. Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. The New England Journal of Medicine, 372(9), 793–795. https://doi.org/10.1056/NEJMp1500523
4. Gibbs, R. A. (2020). The Human Genome Project changed everything. Nature Reviews Genetics, 21(10), 575–576. https://doi.org/10.1038/s41576-020-0275-3
5. Hasanzad, M., Sarhangi, N., & Larijani, B. (2022). Genomic medicine on the frontier of precision medicine. Journal of Translational Medicine, 20, 185. https://doi.org/10.1186/s12967-022-03446-8
6. Hood, L., & Rowen, L. (2013). The Human Genome Project: Big science transforms biology and medicine. Genome Medicine, 5(9), 79. https://doi.org/10.1186/gm483
7. International Human Genome Sequencing Consortium. (2001). Initial sequencing and analysis of the human genome. Nature, 409(6822), 860–921. https://doi.org/10.1038/35057062
8. Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., et al. (2001). Initial sequencing and analysis of the human genome. Nature, 409(6822), 860–921. https://doi.org/10.1038/35057062
9. Mardis, E. R. (2017). DNA sequencing technologies: 2006–2016. Nature Protocols, 12(2), 213–218. https://doi.org/10.1038/nprot.2016.182
10. Metzker, M. L. (2010). Sequencing technologies—The next generation. Nature Reviews Genetics, 11(1), 31–46. https://doi.org/10.1038/nrg2626
11. Ng, S. B., Buckingham, K. J., Lee, C., Bigham, A. W., Tabor, H. K., Dent, K. M., et al. (2010). Exome sequencing identifies the cause of a Mendelian disorder. Nature Genetics, 42(1), 30–35. https://doi.org/10.1038/ng.499
12. Rehm, H. L. (2017). Evolving health care through personal genomics. Nature Reviews Genetics, 18(4), 259–267. https://doi.org/10.1038/nrg.2016.162
13. Roychowdhury, S., & Chinnaiyan, A. M. (2016). Translating genomics for precision cancer medicine. Annual Review of Genomics and Human Genetics, 17, 243–267. https://doi.org/10.1146/annurev-genom-090314-050032
14. Shendure, J., & Ji, H. (2008). Next-generation DNA sequencing. Nature Biotechnology, 26(10), 1135–1145. https://doi.org/10.1038/nbt1486
15. Snyder, M. P., Ashley, E. A., & Butte, A. J. (2018). Medicine gets personal: Genomic medicine. Nature, 562(7727), 181–182. https://doi.org/10.1038/d41586-018-06847-3

16. Stark, Z., Dolman, L., Manolio, T. A., Ozenberger, B., Hill, S. L., Caulfied, M. J., et al. (2019). Integrating genomics into healthcare: A global responsibility. American Journal of Human Genetics, 104(1), 13–20. https://doi.org/10.1016/j.ajhg.2018.11.014
17. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7
18. Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., et al. (2017). Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nature Reviews Cancer, 17(4), 223–238. https://doi.org/10.1038/nrc.2017.7
19. Wright, C. F., FitzPatrick, D. R., & Firth, H. V. (2018). Paediatric genomics: Diagnosing rare disease in children. Nature Reviews Genetics, 19(5), 253–268. https://doi.org/10.1038/nrg.2017.116
20. Zhang, B., & Horvath, S. (2005). A general framework for weighted gene co-expression network analysis. Statistical Applications in Genetics and Molecular Biology, 4(1), Article 17. https://doi.org/10.2202/1544-6115.1128
21. Berger, M. F., & Mardis, E. R. (2018). The emerging clinical relevance of genomics in cancer medicine. Nature Reviews Clinical Oncology, 15(6), 353–365. https://doi.org/10.1038/nrclinonc.2018.20
22. Goodwin, S., McPherson, J. D., & McCombie, W. R. (2016). Coming of age: Ten years of next-generation sequencing technologies. Nature Reviews Genetics, 17(6), 333–351. https://doi.org/10.1038/nrg.2016.49
23. van Dijk, E. L., Auger, H., Jaszczyszyn, Y., & Thermes, C. (2014). Ten years of next-generation sequencing technology. Trends in Genetics, 30(9), 418–426. https://doi.org/10.1016/j.tig.2014.07.001
24. Medical Genome Initiative. (2022). Best practices for the interpretation and reporting of clinical whole genome sequencing. npj Genomic Medicine, 7(1), 27. https://doi.org/10.1038/s41525-022-00295-z
25. Hasin, Y., Seldin, M., & Lusis, A. (2017). Multi-omics approaches to disease. Genome Biology, 18, 83. https://doi.org/10.1186/s13059-017-1215-1.